Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor
Consequently, as the only approved bi-weekly DPP-4 inhibitor, cofrogliptin is well-positioned to substantially improve medication adherence among patients with type 2 diabetes, thereby improving therapeutic outcomes.
Authors
- Pingming Tang
- Jianmin Wang (ORCID: https://orcid.org/0000-0001-8910-0929)
- Chen Zhang (ORCID: https://orcid.org/0000-0001-7609-980X)
- Xiaoxiao Zheng (ORCID: https://orcid.org/0000-0002-5275-1143)
- Xiaoli Gou
- Caixia Dou
- Ju Wang
- Qingyuan Meng
Institutions
- China National Pharmaceutical Group Corporation (China) (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fphar.2025.1702101
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Sciences
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences